期刊文献+

纤溶酶联合复方丹参注射液治疗包裹性结核性胸膜炎的临床疗效 被引量:1

Clinical efficacy of fibrinolytic enzyme combined with compound danshen injection in the treatment of encapsulated tuberculous pleurisy
下载PDF
导出
摘要 目的探讨纤溶酶联合复方丹参注射液治疗包裹性结核性胸膜炎的临床效果。方法选取2018年6月—2020年11月南阳市某医院诊治的80例包裹性结核性胸膜炎患者作为研究对象,采用随机数字表法分为观察组与对照组,每组40例。对照组患者采用纤溶酶注射液治疗,观察组患者在对照组基础上采用复方丹参注射液治疗。比较2组患者的临床疗效、胸腔积液消失时间及治疗前后的胸膜厚度、凝血功能[凝血酶原时间(PT)、纤维蛋白原(FIB)水平、凝血酶时间(TT)]。结果观察组患者治疗总有效率为95.00%(38/40),高于对照组的80.00%(32/40),差异有统计学意义(χ^(2)=4.114,P=0.043)。观察组患者胸腔积液消失时间短于对照组,差异有统计学意义(t=7.240,P<0.001)。2组患者治疗后胸膜厚度均小于治疗前,且观察组小于对照组,差异均有统计学意义(P<0.05)。2组患者治疗后FIB水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);2组患者治疗后PT及TT比较,差异无统计学意义(P>0.05)。结论纤溶酶联合复方丹参注射液治疗包裹性结核性胸膜炎效果显著,可促进胸腔积液吸收,减轻胸膜肥厚,改善患者凝血功能。 Objective To explore the clinical effects of fibrinolytic enzyme combined with compound danshen injec-tion in the treatment of encapsulated tuberculous pleurisy.Methods Eighty cases of patients with encapsulated tuberculous pleurisy treated in a hospital in Nanyang from June 2018 to November 2020 were selected as study subjects and divided into observation and control groups using a random number table,with 40 cases in each group.The patients in the control group were treated with fibrinolytic enzyme injection,and the patients in the observation group were treated with compound danshen injection on the basis of the control group.The clinical efficacy,the disappearance time of pleural effusion,as well as pleural thickness and coagulation functions inclu-ding prothrombin time(PT),fibrinogen(FIB)level and thrombin time(TT)before and after the treatment were compared between the 2 groups.Results The total effective rate of treatment for patients in the observa-tion group was 95.00%(38/40),which was higher than that of 80.00%(32/40)in the control group,and the difference was statistically significant(χ^(2)=4.114,P=0.043).The disappearance time of pleural effusion was shorter in the observation group than in the control group,and the difference was statistically significant(t=7.240,P<0.001).The pleural thickness after treatment was smaller than before treatment in both groups,and it was smaller in the observation group than in the control group,with statistically significant differences(P<0.05).the FIB level after treatment was lower than before treatment in both groups,and it was lower in the ob-servation group than in the control group,with statistically significant differences(P<0.05);the differences were not statistically significant(P>0.05)when comparing PT and TT after treatment in the 2 groups.Conclu-sion Fibrinolytic enzyme combined with compound danshen injection is effective in the treatment of encapsulated tuberculosis pleurisy,as it promotes the absorption of pleural effusion,reduces the thickness of pleura and im-proves the coagulation function of patients.
作者 郭春霞 杨振浩 王琪 Guo Chunxia;Yang Zhenhao;Wang Qi(Department of Infection,The First Affiliated Hospital of Nanyang Medical College,Nanyang Henan 473000,China)
出处 《保健医学研究与实践》 2022年第4期38-40,54,共4页 Health Medicine Research and Practice
关键词 包裹性结核性胸膜炎 复方丹参注射液 纤溶酶 胸腔积液消失时间 胸膜厚度 Encapsulated tuberculosis pleurisy Compound danshen injection Fibrinolytic enzyme Disappearance time of pleural effusion Pleural thickness
  • 相关文献

参考文献12

二级参考文献93

共引文献108

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部